In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more.
Read the full coverage here:
Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations
Opioid use has fallen 15% annually since 2014 in autoimmune rheumatic disease
Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk
S100 protein levels predict abatacept response in juvenile idiopathic arthritis
Izokibep shows early promise in hidradenitis suppurativa
References:
Brunner HI, et al. Arthritis Res Ther. 2024;doi:10.1186/s13075-024-03347-0.
Falasinnu T, et al. Lancet Rheumatol. 2024;doi:10.1016/S2665-9913(24)00120-6.
Tsai SHL, et al. J Am Acad Dermatol. 2024;doi:10.1016/j.jaad.2024.07.1473.